Mechanisms by which food intake elevates circulating levels of hyaluronan in humans

Journal of Internal Medicine

Volumn 258, Issue 5, 2005, Pages 460-466

  Fraser, J R E ^a   Gibson, Peter R ^b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BOX HILL HOSPITAL   (Australia)

Author keywords

Blood flow; Eating; Gastrointestinal motility; Hyaluronan; Lymph flow

Indexed keywords

CISAPRIDE; FAT; GLUCOSE; HYALURONIC ACID; METOCLOPRAMIDE; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GLUCOSE INTAKE; HUMAN; LIPID DIET; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW FAT DIET; LYMPH FLOW; MALE; NORMAL HUMAN; PLASMA; PORTAL VEIN BLOOD FLOW; POSTPRANDIAL STATE; PRIORITY JOURNAL; RADIOMETRY; TEST MEAL;

ADMINISTRATION, ORAL; ADULT; AGED; CISAPRIDE; DIETARY FATS; EATING; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; GLUCOSE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRAVENOUS; MALE; METOCLOPRAMIDE; MIDDLE AGED;

EID: 27544456388     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01564.x     Document Type: Article

References (52)

1. Nyberg A, Engström-Laurent A, Lööf L. Serum hyalurunate in primary biliary cirrhosis - a biochemical marker for progressive liver damage. Hepatology 1986; 8: 142-6.
2. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25: 684-8.
3. Ishibashi K, Kashiwagi T, Ito A et al. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology 1996; 24: 27-31.
4. Stickel F, Poeschl G, Schuppan D et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol 2003; 15: 945-50.
5. Patel K, Lajoie A, Heaton S et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003; 18: 253-7.
6. Gordon A, Bailey MJ, Gibson PR, Roberts SK. Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 825-32.
7. Oberti F, Valsesia E, Pilette C et al. Noninvasive diagnosis of hepatic tibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-16.
8. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995; 22: 22-6.
9. Plevris JN, Haydon GH, Simpson KJ et al. Serum hyaluronan - a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 2000; 12: 1121-7.
10. McHutchison JG, Blatt LM, de Medina M et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945-51.
11. Xie SB, Yao JL, Zheng SS, Yao CL, Zheng RQ. The levels of serum tibrosis marks and morphometric quantitative measurement of hepatic fibrosis. Hepatobiliary Pancreat Dis Int 2002; 1: 202-6.
12. Lun-Gen L, Zheng M-D, Wan M-B et al. Grading and staging of hepatic fibrosis, and its relationship with non-invasive diagnostic parameters. World J Gastroenterol 2003; 9: 2574-8.
13. Rosenberg WM, Voelker M, Theil R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13.
14. Guechot J, Serfaty L, Bonnand AM, Chazouilleres O, Poupon RE, Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32: 447-52.
15. Adams DH, Wang L, Hubscher SG, Neuberger JM. Hepatic endothelial cells: targets in liver allograft rejection? Transplantation 1989; 47: 479-82.
16. Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003; 15: 395-403.
17. Lokeshwar V, Schroeder G, Hautmann S, Selzer M. Hyaluronic acid and hyaluronidase: accurate tumor markers and tumor progression regulators. Scientific World Journal 2001; 1 (Suppl. 3): 106.
18. Martins JR, Furlanetto RP, Oliveira LM et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Clin Endocrinol 2004; 60: 726-33.
19. Engström-Laurent A, Hällgren R. Circulating hyaluronic acid varies with physical activity in health and rheumatoid arthritis. Relationship to synovitis and morning stiffness. Arthr Rheum 1987; 30: 1333-8.
20. Piehl-Aulin K, Laurent C, Engström-Laurent A, Hellström S, Henriksson J. Hyaluronan in human skeletal muscle of lower extremity: concentration, distribution, and effect of exercise. J Appl Physiol 1991; 71: 2493-8.
21. Reed RK, Laurent TC, Taylor AE. Hyaluronan in prenodal lymph from skin changes with lymph flow. Am J Physiol 1990; 259: H1097-100.
22. Rössler A, László Z, Kvas E, Hinghofer-Szalkay HG. Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. Eur J Appl Physiol 1998; 78: 573-7.
23. Wong CSM, Gibson PR. The effects of eating on plasma hyaluronic acid in patients with cirrhosis, its mechanism and influence on clinical interpretation. J Gastroenterol Hepatol 1998; 13: 1218-24.
24. Idobe Y, Murawaki Y, Ikutaq Y, Koda M, Kawasaki H. Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med 1998; 37: 568-75.
25. Phillips MG, Preedy VR, Hughes RD. Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy? Eur J Gastroenterol Hepatol 2003; 15: 941-4.
26. Brandt R, Hedlöf E, Asman I, Bucht A, Tengblad A. A convenient radiometric assay for hyaluronan. Acta Otolaryngol (Stockh) 1987; 442 (Suppl.): 31-5.
27. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-5.
28. Tengblad A, Laurent UB, Lilja K, Cahill RN, Engström-Laurent A, Fraser JRE et al. Concentration and relative molecular mass of hyaluronate in lymph and blood. Biochem J 1986; 236: 521-5.
29. Delpech B, Bertrand P, Maingonnat C. Immunoenzyme assay of the hyaluronic acid-hyaluronectin interaction: application to the detection of hyaluronic acid in serum of normal subjects and cancer patients. Anal Biochem 1985; 149: 555-65.
30. Engström-Laurent A. Changes in hyaluronan concentration in tissues and body fluids in disease states. In: Evered D, Whelan J, eds. Ciba Foundation Symposium 143: The Biology of Hyaluronan. Chichester: Wiley and Sons. 1989: 233-40.
31. Engström-Laurent A, Laurent UBG, Lilja K, Laurent TC. Concentration of sodium hyaluronate in serum. Scand J Clin Lab Invest 1985; 45: 497-504.
32. Lindqvist U, Laurent TC. Serum hyaluronan and aminoterminal propeptide of Type III procollagen. Variation with age. Acta Univ Upsal 1992; 333: 1-20.
33. Laurent UBG, Laurent TC. On the origin of hyaluronate in blood. Biochem Int 1981; 2: 195-9.
34. Fraser JRE, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981; 200: 415-24.
35. Fraser JRE, Engström-Laurent A, Nyberg A, Laurent TC. Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med 1986; 107: 79-85.
36. Smedsrød B, Pertoft H, Eriksson S, Fraser JRE, Laurent TC. Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J 1984; 223: 617-26.
37. Laurent TC, Fraser JRK, Pertoft H, Smedsrød B. Binding of hyaluronate and chondroitin sulphate to liver endothelial cells. Biochem J 1986; 234: 653-8.
38. Fraser JRK, Alcorn D, Laurent TC, Robinson AD, Ryan GB. Uptake of circulating hyaluronic acid by the rat liver. Cellular localization in situ. Cell Tissue Res 1985; 242: 505-10.
39. Lebel L, Fraser JRE, Kimpton WS, Gabrielsson J, Gerdin B, Laurent TC. A pharmacokinetic model of intravenously administered hyaluronan in sheep. Pharm Res 1989; 6: 667-82.
40. Lebel L. Turnover of circulating hyaluronan. Studies in man and experimental animals. Acta Univ Upsal 1989; 217: 50-2.
41. Jäger K, Bollinger A, Valli C, Ammann MD. Measurements of mesenteric blood flow by duplex scanning. J Vasc Surg 1986; 3: 462-9.
42. Wiseman LR, Foulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52.
43. Scarpignato C. Pharmacological stimulation of gastrointestinal motility: where we are and where are we going? Dig Dis 1997: 15 (Suppl. 1): 112-56.
44. Lebel L, Smith L, Risberg B, Gerdin B, Laurent TC. Effect of increased hydrostatic pressure on the lymphatic elimination of hyaluronan from sheep lung. J Appl Physiol 1988; 64: 1327-32.
45. Reed RK, Townsley MI, Laurent TC, Taylor AF. Hyaluronan flux from cat intestine: changes with lymph flow. Am J Physiol 1992; 262: 11457-62.
46. Bond JH, Prentiss RA, Levitt MD. The effects of feeding on blood flow to the stomach, small bowel and colon of the conscious dog. J Lab Clin Med 1979; 93: 594-9.
47. Varro V, Csernay L, Szarvas F, Blahó G. Effect of glucose and glycine solution on the circulation of the isolated jejunal loop in the dog. Am J Digest Dis 1967; 12: 60-4.
48. Simmonds WJ. The effect of fluid, electrolyte and food intake on thoracic duct lymph flow in unanaesthetized rats. Aust J Exp Biol 1954; 32: 285-300.
49. Simmonds WJ. The relationship between intestinal motility and the flow and rate of fat output in thoracic duct lymph in unanaesthetized rats. Q J Exp Physiol 1957; 42: 205-21.
50. Reed RK, Townsley MI, Pitts VH, Laurent TC, Taylor AE. Increased flux of hyaluronan from cat intestine during fat absorption. Am J Physiol 1992; 263: G6-11.
51. Reed RK, Lilja K, Laurent TC. Hyaluronan in the rat with special reference to the skin. Acta Physiol Scand 1988; 134: 405-11.
52. Clausen JP, Klausen D, Rasmussen B, Tyrap-Jensen J. Central and peripheral circulatory changes after training of the arms or legs. Am J Physiol 1973; 225: 675-82.